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INTRODUCTION 
Loxver respiratory tract infections (LILTIS) arc 3111011g 
the most coninion infections in humans, comprising 
~ippi-oximxely 13'% and 2.5% of ,111 coiiimunity- 
acquired md nosocomial infections, respectively [ 11 .  
Exly  diagnosis i c  often essential to avoid the sexwe 
morbidity 'ind the risk of hospitalization mociated 
\vith ii)'iiiy LRTIs.  Identification of the relevmt 
pcdiogene before antibiotic therapy is initiated is still 
probleiiiatic, hoLvever. and treatment is frequently 
eiiipiricd. Consequently, antibiotics with a spectrum 
adapted to the range of pulmonary pathogens :ire 
generally preferred. 
The  ability to penetrate into pulmonary tissuec, 
cells, and fluids, reaching concentrations which inhibit 
01- kill the cmsxive organisms, \eeiiis t o  be 'in 
iniportant charcicteri~tic of the ideal mtiniicrobial  agent 
for the tresitment of LILTIS. although i ts  cliiiic,il 
I-elevmcr in human\ h a c  not been fully c i ssewd.  
Fluoroquinoloiirs penetrate very \veil into the lung, 
a id  may 'ichieve bronchial and pulmonary concentr.i- 
t ioi is  that equal or exceed ceruiii coticeiitrsitions [ 21. I n  
xidition, ~ntracellular coiicentratioiis <ire 'ilso within 
the thercipeutic range fix- the niajority of intracellular 
pathogens causing LRTls. Converwly, most p-I'ictani 
mtibiotics do not exceed 30'% of their serum level 
within bronchial secretions. and some agents, such n\ 
miinoglycosides, only re'icli 30-40'X of their seruni 
level in the lung, m d  less in the inter- m d  intracell~il~ir 
milieu [2,3]. 
There i\. 'it present, '1 gei ier~l  trend to reduce thc 
duration of therapy in order to reduce the possible 
developnient of adverse events a id  resistmce, xvhilst 
niaintaiiiing clinical ef'fcacy, and to improve the cost- 
etfectiveness of treatnient a n d  decrease hospit'ilization 
time. Also iinportant is the increasing use of step-down 
or switch therapy, \171iereby treatiiient if \tarted with 
intravenous ,idmi~iisti-ation and then continued Ivith an 
oral foriiiulation 111. Thi\  h,is s e w r d  adv'intages, 111- 
cluding pl~armacorconoi i~ic  ~dvxitages ~ n d  iinpi-ovcci 
patient c-oiiiplimce. 
This paper focuscs on the c'iusativc pcithogerir 111 
LILTIS. the current approaches t o  trcatnient, nnd the 
experience to datc with fluorocluiilolones. Although 
the ~ i s e  of soiiie fluorocluiiioloiie\. p t i c u l a r l y  cipro- 
floxacin, iii the ti-e~tiiient of  c> ctic fibrosis i \  xvell 
docuniciited. the topic \ v x  i i o t  di\cur\ttd 'it thi5 
nicctiiig, \vhich \ v ~ e  foc-uwd 011 thc  treatment o f  
infections in adult pitient\. 
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CHRONIC BRONCHITIS (ACUTE EXACERBATIONS) 
Definition and diagnosis 
Chronic bronchiti\ is per\istclit inflamnicition xi3 
irritation of the bronchial tree \xrhich is clmically 
de f ind  as hymptoiiis of  cough with sputum production 
2S42 
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during 3 consecutive months over 2 consecutive years 
with periodic acute exacerbations during which 
\ymptoms worsen [5]. It  is generally a progressive 
condition which is closely linked to smoking, and is 
most frequently found in older men (> 40 years old). 
Chronic bronchitis is very common, affecting up to 
25% of the adult population. During periods of acute 
exacerbation, when inflammation and infection are 
worsened, antibiotic therapy is usually instituted. Signs 
and symptoms of acute exacerbations include: a change 
in the amount, consistency and color of the sputum; 
increased dyspnea; productive cough; tachypnea; chest 
tightness; increased fatigue; and, especially in the 
elderly, confusion. In addition, physical examination 
may reveal rales and ronchi and, at times, prolonged 
exhalation. 
Etiology 
The bacterial species commonly associated with acute 
exacerbations of chronic bronchitis are relatively non- 
virulent, usually forming part of the flora of the upper 
respiratory tract [6]. Non-typeable Huermpki /us  influ- 
enzue accounts for approximately 70% of isolates from 
patients with acute exacerbations of chronic bronchitis. 
The airways are thought to become colonized through 
interaction between specific bacterial adhesions and 
epithelial cell receptors [7]. When H .  injuenzue is 
introduced into the respiratory tract, it is normally 
removed rapidly by mucociliary clearance, but in 
individuals with impairment of this host defense 
mechanism it reniains attached longer to pooled 
mucus, allowing surface contact with areas of damaged 
bronchial epithelium. Further damage to the epi- 
thelium, resulting from bacterial toxins and metabolic 
products, could help the bacterium to spread through 
the respiratory tract [6]. Streptococcus pneumoiziae is 
another commonly encountered bacterium responsible 
for purulent exacerbation, and Moruxellu cutuYrlzulis may 
also be implicated in a smaller number of cases [8,9]. 
Klebsiella pneumoniue, Stupliylococcus uureus and Pseudo- 
inonus uevugiriosu are infrequent causes. Other bacteria 
that can be involved in acute exacerbations of chronic 
bronchitis as either exclusively predominant or mixed 
pathogens include Neisseria spp., Bordetelln spp., 
Rliodococci spp. and anaerobes. The role of Mycoplasina 
pnerrriioniae and Clzlamydiu pnerirnoniue in chronic 
bronchitis should be considered. 
Treatment 
Oral penicillins are effective against Gram-positive 
cocci and bacilli and are used to treat infections caused 
by penicillin-susceptible pneumococci and streptococci 
in adults and children [lo]. They are not active against 
P-lactaniase-producing niicroorganisnis or ‘atypical’ 
pathogens. Oral cephalosporins are often used and 
the oral first-generation cephalosporins (cefalexin, 
cefadroxil, cefradine and cefaclor) are effective against 
penicillin-susceptible Gram-positive organisms but 
show restricted efficacy against penicillin-resistant 
Streptocoecrrr przemoniae,  Enterobacteriaceae and p- 
lactaniase-positive H .  ir$uenzue [ 101. Trimethoprini, 
sulfamethoxazole and anioxycillin/clavulanic acid are 
also time-honored treatments. 
Fluoroquinolones 
In the treatment of acute exacerbation of chronic 
bronchitis, ciprofloxacin (500 ing twice daily) has been 
shown to be as effective as amoxycillin/clavulanic acid 
(875 mg/125 mg twice daily) or cefixime (400 nig 
once daily) in a study of 218 outpatients [ l l ] .  Eradica- 
tion rates of 81%, 82% and 78% were reported with 
ciprofloxacin, aiiioxycihn/clavulanic acid and cefixime, 
respectively. Moreover, clinical success was obtained in 
86%) of patients treated with ciprofloxacin, 91% of the 
cases treated with amoxycillin/clavulanic acid, and 81% 
of the cefixime group. 
Ofloxacin has also been shown to be effective 
[12-141. Chodosh reviewed the use of enoxacin, 
ciprofloxacin, ofloxacin and temafloxacin in acute 
exacerbations of chronic bronchitis, and the last three 
were generally more effective than enoxacin [15]. 
DeAbate et a1 compared sparfloxacin and ofloxacin in 
a double-blind study. Overall response rates, defined as 
cure or iniprovernent of clinical signs and symptoms 
and eradication or presunied eradication of pathogens, 
were 85.4% and 88.8%, respectively [16]. The com- 
bined eradication and presumed eradication rates were 
89.9% and 92.5%, respectively. 
The results of two multicenter studies of levo- 
floxacin in the treatment of acute bacterial exacerba- 
tions of chronic bronchitis are summarized in Table 1 
[17,28]. In the first study, in which levofloxacin was 
compared with cefaclor, the greatest difference in terms 
of response of individual pathogens was seen with H. 
in&renzue (100% versus 71% eradication) [ 171. Eradic- 
ation rates for Streptococci~s pneuinoniae and Stupliylococcus 
anreus were 90% and 89%, respectively, for levofloxacin, 
compared with 86% and 67% for cefaclor. Moreover, 
overall rates of bacteriologic resistance were 24% in the 
cefaclor group and 2%) in the levofloxacin group. In  
the second study, levofloxacin was found to have 
comparable efficacy to that of cefuroxirne axetil, with 
clinical success in 95% of levofloxacin-treated patients 
and 93% of patients treated with cefuroxime axetil [18]. 
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Table 1 Levofloxdcin in the treatment of acute exacerbation5 of chronic bronchitir [17,18] 
~~~ ~~~~ 
I h r a t i o n  Clinical Bacteriologic Overall ratr of M a t  c0111111011 
(tiicaii d ~ y ~ )  respo~isc (no ) response (no.) adverw Cvents (no.) adverse mtmt 
Study 1 (Habib et al [ 171) 
Oral Irvoflouciii. 500 m g  O . C .  6.0 ')?%I (1 54) 04'% ( 1  11.3) 7";) (187) Nausea ( 2 ,  l'%,) 
0 r . d  cebclor, 25C1 iiig t .1.d.  8.7 92%) (155) 87% (89) 4 . w  (186) Ilicmhe.i (2.2%) 
Study 2 (IkAbate et al [ 1 XI)  
Ora l  I e ~ ~ f l o x a ~ i i i .  500 ing o.d. 7 95%) (222) '16% (13-1) 0.Yh (NR) Vagriiti\ (4%) 
Oral cefiirosinie nsctil, 250 mg b.1.d I0 93% (220) 93%) (147) 7.0'X (NIL) I h r r h e d  (3%) 
NIX. iiot reported. 
0.d. once d'lllv. 
ACUTE BRONCHITIS 
Definition and diagnosis 
Acute bronchitis is characterized by an acute inflani- 
niation of  the bronchi, usually caused by viral infections 
wch as influenza, rhinovirus or the 'common cold'. In 
general, it is clinically characterized by the presence of  
an acute, non-productive cough in patients without 
underlying lung disease. On the other hand, bacterial 
infection usually causes fever and soinetinies chills 
and is usually an acute. severe illness compared with 
viral infection, which is accompanied by a low fever 
and milder symptonis in the early stages. Sputum is 
purulent and plentiful in bacterial infection and rare in 
viral infection. 
Etiology 
Acute bronchitis is a viral illness (influenza virus, 
adenovirus and rhinovirus account for the majority of  
cases). T h e  incidence of  primary bacterial infection 
is difficult to assess. T h e  roles of W .  ir$iretrzuc and 
Stveptococcrrs przerrrnorziue are unclear and those of  A l p -  
p/n.wu priewnonine, Clilarri ydia prreuvnorria and B. perfussis 
also need to be considered. 
Treatment 
Viral respiratory infections usually have a benign 
course without fever and purulent sputum production. 
Symptoms decline within 7 day? of  onset. Antibiotics 
are riot usually recommended. In prolonged cases, or 
documented bacterial infection, p-lactams and macro- 
lides have been used. 
NOSOCOMIAL PNEUMONIA 
The microbiological etioIoL7 of pneumonia i c  extremely 
variable, depending on  whether it is coiiiiiiunity 
acquired or nosoconiial 1191 T h e  virulence of  the 
c'iusative orgcuiisrii 15 the main determinant of  the 
diseaw procecs, although there may be a predisposition 
to pneunionia cauced by 1 educed hoct defenses, 
particularly suppression of  the cough reflex, impair- 
ment  of iiiucociliary clearance, the presence of  a 
foreign body or  reduced systemic and local immunity. 
Definition and diagnosis 
Patients with nosoconiial pneunionia usually have 3 
variety of severe underlying diseases and are often 
iiniiiunocoiiiproinised. Thcy a h  receive a wide range 
of  medication and supportive management which 
increases their susceptibility to  infectious complication: 
intubation, in  particular, poses an extreme risk for the 
development of pneumonia. Clinical signs and symp- 
toms are characterized by a sudden onset of malaise, 
fever, chills, increased sputum production and leuko- 
cytosis. In almost all cases, an infiltrate is recognizable 
on chest X-rays. 
Etiology 
T h e  spectrum of  nosocomial pneumonia pathogens 
includes, in addition to moit  bacteria causing 
community-acquired pneumonia, Gi-an-negative 
bacteria such as K. prirrrmorrioc, Esclrevicliin coli, 
ilcinefohactev spp., J? nengiriosa and related organisms, 
Sfaplzylococcns urirez4s and, occasionally, fungi. However, 
Gram-negative bacteria are the predominant pathogens, 
while Stveptoroccru yrreninoriiae and H .  ir!fliierizne are 
not generally considered significant. A polymicrobial 
etiology is detected in 10-30'X of cases of nosoconiial 
pneumonia. 
Treatment 
Nosocomial pneumonia i c  the second most important 
nosoconiial infection. I t  prolongs hospital stay and is 
also associated with substantial mortality. I n  niost cases, 
parenteral drug administration i c  ured. T h e  choice of  
antibiotic and dosage regimen vary depending on 
the spectrum of potential pathogens, and the assess- 
ment of a variety of factors, including the severity of  
the pneumonia, the presence of  specific coexisting 
illness, prior therapy (including mtibiotics), and the 
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duration of hospitalization. Monotherapy with second- 
generation cephalosporins has been shown to be highly 
successful in cases without severe underlying illness 
[20]. Patients who belong to special risk groups, such 
as patients with underlying diseases or elderly patients 
with pronounced clinical symptoms, are often treated 
with second-generation cephalosporins in conjunction 
with aminoglycosides, or ureidopenicillins (piperacillin, 
azlocillin, mezocillin) in combination with amino- 
glycosides, or with third-generation cephalosporins, 
with or without the addition of a macrolide. Erythro- 
mycin and other macrolides have good activity against 
streptococci, pneumococci and Legionella, Mycoplasma 
and Chlamydia spp. but borderline activity against H .  
infuenzae [21]. Erythromycin has the disadvantage of a 
gastrointestinal intolerance rate of up to 30%. The 
new macrolides have fewer gastrointestinal side effects 
[22]. For patients with severe concomitant diseases 
and respiratory insufficiency, third-generation cephalo- 
sporins such as ceftazidime, cefepime, cefpirome, 
ceftriaxone or carbapenems, at high dosage, may be 
prescribed as monotherapy or in combination with 
other antibiotics. An alternative therapy in patients 
who cannot be treated with p-lactams is the use of 
intravenous and, subsequently, oral fluoroquinoiones. 
Fluoroquinolones 
Ciprofloxacin has been shown to be as effective as 
imipenem as monotherapy in treating severe noso- 
comial pneumonia [23]. In a multicenter study of 189 
patients with severe hospital- (84%) or community- 
acquired (1 6%) pneumonia, intravenous ciprofloxacin 
at  high doses (400 mg every 8 h) resulted in signi- 
ficantly better rates of clinical cure or improvement 
than that achieved with imipenem (1 g every 8 h) and 
a significantly higher rate of bacteriologic eradication 
[24]. This was thought to result from the significantly 
higher rate of bacteriologic eradication of Entero- 
bacteriaceae in the ciprofloxacin group (93% versus 
6696, p=0.001). In an open study in 50 patients, 
Peloquin et a1 showed that intravenous ciprofloxacin 
200 mg twice a day was effective against Gram-negative 
pathogens, although I? aeruginora was eradicated in 
less than 50% of patients [25]. Gentry et a1 reported 
that ofloxacin (400 mg b.i.d.) was effective in noso- 
comial pneumonia, and Petermann reported an overall 
satisfactory response rate of 93% in 109 patients treated 
with ofloxacin 200 mg twice a day [26,27]. 
COMMUNITY-ACQUIRED PNEUMONIA 
Definition and diagnosis 
Pneumonia is defined as inflammation and consolid- 
ation of the lung tissue due to an infectious agent. 
Symptoms indicative of pneumonia are fever, chills, 
pleuritic chest pain and cough with purulent sputum. 
Microbiological diagnosis is often difficult, particularly 
if the patient does not produce sputum. 
Etiology 
Streptococcus pneumoniae is responsible for the majority 
of cases of community-acquired pneumonia (CAP). 
Complications usually result from invasion of the blood- 
stream, causing bacteremia with shock, meningitis and 
septic arthritis. H. infuenzae infection is another major 
cause, and other common pathogens include Moraxella 
catarrhalis and respiratory viruses. Staphylococcal pneu- 
monia is associated with viral (influenza) infection. 
Gram-negative pathogens are found most frequently in 
high-risk patients such as the elderly or multimorbid 
patients, or during immunosuppressive treatment [28]. 
Up to 10% of cases of CAP may be caused by two or 
more aerobic pathogens, with Streptococcus pneumoniae 
and H. infuenzae being the most commonly identified 
combination. The most common atypical pathogen is 
Mycoplasma pneumoniae, followed by Chlamydia pneu- 
moniae and L. pneumophila, and together they account 
for approximately 30-40% of cases. The incidence of 
Coxiella burnetii is diversely reported. 
Treatment 
Although a Gram stain of bronchial secretions can 
help direct therapy, the treatment strategy for CAP is 
necessarily empirical in most cases, including in the 
outpatient setting. Immediate therapy is necessary as 
soon as possible after diagnosis because of the potential 
for severe morbidity, particularly at  onset. An antibiotic 
with a spectrum adapted to the potential pathogens is 
generally recommended. There are no characteristic 
and specific clinical features that correlate with the 
etiologic diagnosis. Erythromycin and clarithromycin 
have been shown to be effective against most of the 
causative pathogens, including Mycoplasma, Chlamydia 
and Legionella. Aminopenicillins or oral cephalosporins 
may be used when atypical pathogens are not thought 
to be the causative organisms. 
Various countries have developed guidelines for 
the empirical treatment of CAP The American 
Thoracic Society, the British Thoracic Society, the 
Canadian Community-acquired Pneumonia Consensus 
Group and the French guidelines are summarized in 
Table 2 [29-311. The existence of different guidelines 
which incorporate varying recommendations high- 
lights the need for consensus in this therapeutic area. 
Fluoroquinolones 
Fluoroquinolones are characterized by an antibacterial 
spectrum adapted to most respiratory pathogens and 
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Table 2 Recoinmendations for the empirical treatment of community-acquired pneumonia 129-3 1 ] 
Llritidi Thoracic Socicty (1 993) 
Uncomphc.irrd piieunionu of unknown etiology without features Indic-mng severe 01- iioii~pneuiiiococc.il dis 
I’refe1-1-ec1: a n  aniinoprnicillin (miosycilhn 500 iiig orally t.i.d. or mipicillin 500 iiig 1V q.i.d. or benzylpcnic~llin 1.2 g IV q.i.d.) 
Altrr i im~c\ :  cr\:tliron~ycin (500 iiig orallv or IV q.i.d.) or second- or third-generation cephalosporin (cctiii-oxiin~ or cehtxuiiiie) 
1’rc.fci-reii: erythi-oniycin ( 1  g IV c1.i.d.) + \rcoiidL 01- tliii-d-getirr‘itioii cwphalocporiii (cehirosniir I i g 01- crfot.i\imc 2 g 1V t.i ii i 
Altcrnati\-e: ampicillin I 2, fluclosnrilliii 2 9, a n d  erythuoniycin 1 g, ~ l l  IV q . i . c i .  
Severe pnerimoni.i o f  unkno\vn etiolog 
Fi-cnch Latigii.ige Society of-lnfectiouc I l i s e ~ s ~ s  (1992) 
Apparentl\: health)- xitilts with no kiturc\ indieciting cevrrr (ii 
IlebilitmA higli-ri\k adult\ 
se\ T I C  
.i\mox:).cillin (uwally 1 g t . i .d.)  or a niacrolide. Tremricnt \hould be reappraised ‘ifti‘]- 48-72 h 
A m o ~ ~ r i l l i n / c l ~ i v i ~ l ~ n i c  ‘ilcid or oral cephalosporiti. Macrolidr oi- Huoroquinolonc if L p i c i ~ i m i p / i i / ~ 7  wcpec-ted 
l’arenttx.il combination therapy. Anioxyc~llin/clavulaii~c acid o r  thircl-generation cephalosporin + ii~ici-olidc 01- fiuoroqiiinolorit~ 
Adapted from 13.ii-tlrtt and otliim 129-3 I I 
rapid bactericidal activity. They  re active against 
Gram-negative bacilli, including H .  ir!flirenrne, Entero- 
bacteriaceae, I’serrdormrm spp. and ArirletoDuc-rev spp., and 
Grmi-positive bacteria, including Stuyhyloc-orc-irs urireirs, 
coagulate-negative staphylococci and some strepto- 
cocci, with variable activity against Streytorocirrs yrrcrr- 
rrrorriac. They have good activity against H .  ir!flireriznc,, 
A4y~c~p lusr i i~  cutnrrlidis and all the pathogens that cause 
atypical pneumonia. Prior to the introduction of cipro- 
floxacin, their spectrum w ~ s  liniited, as it did not 
encompass the ~ n a i n  respiratory pathogens. When 
ciproflosacin was  introduced, it mas initially hoped 
that it might provide 3x1 adequate therapy for CAP. 
However, problems with clprofloxacini poor activity 
again7 t .Srveptococc~i~ p i  I C Y  r i l i o i  I iiic 111 ean t that ciprofloxacin 
itself, and the fluoroquinolones ‘is a class, would not 
bc suitable for the treCitnieiit of pnruiiiococcal pneu- 
monia. This situation is now changing with the 
introduction of the newer fluoroquinolones, with 
improved activity against these pathogens, particularly 
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Table 3 In vitro activity (MICg,, range or mean (mg/L)) of selected fluoroquinolones against respiratory tract pathogens 
[ 19,32-40] 
Organism Ciprofloxacin Levofloxacin Sparfloxacin Trovafloxacin 
Streytococcirs yiicirniorriae 0 . 5 4  1.91 0.25-1 0.2 
Staphylucucciis aiirerrs, niethicillin susceptible 0.25-2 0.1 2 4 . 7 8  0.06-0.25 0.12 
Stapkylororcns atircirs, methicillin resistant 0.5-16 0.39-0.78 0.06-0.25 0.03 
H .  ir!flrieiizac 0.003-0.006 0.02-0.05 n.oo8-o.o6 0.05 
L!4urme//a ca tarrhah 0.014.25 0.02-0.11 0.0 1 4 . 1 2  0.05 
Mycoylasrwa piicwiiuttiac 0.78-2 0.5-1 0.1-0.25 0.25 
Chlaitiydia prrctriiioriiae 2 0.5 (3.014.25 0.5-1 
Le'!+lc//u spp. 0.05 0.0541.1 0.025 0.004 
L. piteirriiuphilil 0.008-0.06 0.125 o.oo4-0.06 0.004 
MIGN = miniiiium concentration required to inhibit 90% of pathogens. 
Streptococcus pneurnoniae. Table 3 summarizes the in 
vitro activity of one of the established fluoroquinolones, 
ciprofloxacin, and the activities of three new fluoro- 
quinolones, levofloxacin, sparfloxacin and trovafloxacin 
against the main respiratory tract pathogens [19,32-401. 
Ciprofloxacin has been extensively prescribed in 
the treatment of LRTIs [41]. However, a succession of 
anecdotal reports of relatively poor performance of 
ciprofloxacin against Stveptoccccus pneumoniae led to a 
change in the package labeling in the USA, cautioning 
against the use of currently a.iailable fluoroquinolones 
in the treatment of pneumococcal infections [42-451. 
This was also partly responsible for an increase in the 
recommended dosage regimen of intravenous cipro- 
floxacin from 200 mg twice daily to 400 mg twice or 
three times daily. 
Several studies have reported the use of ofloxacin 
in the treatment of CAP In a comparative study with 
erythromycin, Nielsen et a1 showed combined cure/ 
improvement rates of 96% for ofloxacin and 82% for 
erythromycin [46]. Plouffe et a1 showed that ofloxacin 
was as effective as standard therapy (p-lactam alone or 
plus a niacrolide) in patients hospitalized for CAP 
(clinical success rates of 92% and 87%, respectively) 
[47]. An overall satisfactory response rate of 93% in 212 
patients was reported by Petermann [27]. 
Carbon et a1 compared temafloxacin and amoxy- 
cillin in a study of 246 hospitalized patients [48]. 
Overall, there were no significant differences between 
temafloxacin and amoxycillin in clinical recovery rates 
(8596, 80%) and bacterial eradication rates (98%, 96%). 
Both were equally effective in treating pneumococcal 
infections. Although several additional studies demon- 
strated the efficacy of temafloxacin in CAP, this 
antibiotic was withdrawn from use in 1992 due to the 
high incidence of serious adverse events. 
Sparfloxacin is active against all major LRTI 
pathogens, including atypical organisms such as L. 
pneumophila, Mycoplasrna pneumoniae and Chlarnydia 
pneumoniae [49]. However, severe phototoxic reactions 
have been associated with its use which have led to 
prescribing restrictions. Sparfloxacin shows rapid and 
high diffusion into respiratory tract tissues and fluids, 
with concentrations of 2.6 mg/L in bronchial mucosa, 
9.8 mg/L in the epithelial lining fluid and 61.3 mg/L 
in alveolar macrophages 12 h after an oral loading dose 
of 400 mg [50]. 
Several studies in CAP have been performed with 
this antibiotic. Two double-blind studies compared the 
efficacy of sparfloxacin (200 mg once daily, following 
a 400-mg loading dose) with that of amoxycillin/ 
clavulanic acid (500/125 mg three times daily), erythro- 
mycin (1000 mg twice daily) or amoxycillin (1000 mg 
three times daily) [51]. The results of these studies 
were pooled to encompass 1137 episodes of CAP in 
hospitalized patients (560 were treated with sparfloxacin 
and 577 were randomized to the comparator agents), 
showing that sparfloxacin had similar efficacy to that of 
the comparators, with global efficacy rates of 88% and 
84%, respectively. 
Another study compared sparfloxacin 200 mg once 
daily with a combination of amoxycillin 1 g three times 
daily and ofloxacin 200 mg twice daily for 10 days [52]. 
The placebo-controlled, double-blind randomized 
study was conducted in 21 1 hospitalized elderly patients 
or in cases of first antibiotic treatment failure. O f  
the isolated pathogens, 40% and 36% were identified 
as Streptococcus pneumoniae in the sparfloxacin and 
amoxycillin plus ofloxacin groups, respectively. At the 
end of treatment, the overall efficacy rates (defined as 
successful clinical cure and resolution or improvement 
of signs or symptoms) for the sparfloxacin and amoxy- 
cillin plus ofloxacin treatment groups were 92% and 
8296, respectively. Oral treatment with sparfloxacin in 
CAP (caused by Streptococcus pneumoniae in 20% of 
cases) has also been shown to be superior to roxi- 
thromycin (82%1 success rate versus 72%) in another 
controlled study of 304 patients [53]. 
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Levofloxacin, the /-isomer of  oflosacin, is gener- 
ally twice as potent as ofloxacin, with a broad range of 
activity against most Gran-negative and Gram-positive 
bacteria, including atypical organisms 1341. Like that 
of  ofloxacin, the oral bioavailability of  levofloxacin 
approaches IOO'X), perniitting oral dosing for all but the 
most seriously ill and debilitated patients [54,55]. In 
addition, levofloxacin has good penetration into lung 
tissue, bronchial mucosa, epithelial lining fluid and 
alveolar niacrophages after a 500-mg single dose. In 
a mouse pneumonia niodel, oral levofloxacin (20 
and 40 mg/kg) significantly reduced the number of  
viable Strcptororcrrs pnerm~iniae organisms in the lungs, 
whereas ciprofloxacin was n o  more effective than n o  
therapy 1341, 
Animal studies and recent pharmacokinetic 
studies in humans also suggest that, unlike enoxacin 
or  ciprofloxacin, levofloxacin does not significantly 
impair theophylline metabolism [34,56]. Levofloxacin 
may also have a much lower potential for photo- 
sensitivity reactions in comparison with other fluoro- 
quinolones, such as loniefloxacin, sparfloxacin and 
enoxacin [57]. 
Two published studies have demonstrated the 
efficacy of levofloxacin in CAP In a n  open, nori- 
comparative, multicenter study in 68 patients, intra- 
venou? or  oral levofloxacin once daily was highly 
effective in mild-to-moderate and severe CAI', with a 
successful clinical response in 100% of the 60 clinically 
evaluable patients [58]. All the pathogens isolated in this 
study, including Streptococcus pnenmonine, H .  ir$ueizzue, 
Stnphylorocrirs unreiis and Cklnniydin pueumoniae, were 
eradicated. Intravenous or  oral levofloxacin (500 m g  
once daily) waE compared with parenteral ceftriaxone 
(1-2 g once or twice daily) and/or cefuroxime axetil 
( S O 0  nig twice daily) in a randomized, open label, 
active-control trial in patients with a primary diagnosis 
of  CAP 1591. Patients received the study medications 
for 7-1 4 days; levofloxacin 500 nig once daily either as 
a 1-h infusion or  orally; ceftriaxone 1 or  2 g once or 
twice daily; oral cefuroxiine axeti1 500 m g  twice daily. 
Cherall ,  456 patient$ were evaluable fbr efficacy (226 
Ievofloxacin, 230 ceftriaxone/cefuroxime). Clinical 
succcss (defined as cure or iniprovernent) was achieved 
in 96% of patients treated with levofloxacin and 90% of 
those treated with ceftriax-one/cefui-ox-ime. The  pre- 
treatment pathogen was eradicated in 98% of  those 
treated with levofloxacin cainpared with 85% of those 
treated with ceftriaxone/cefuroxinie. An eradication 
rate of 100% was achieved for the two most comiiion 
pretreatment pathogens, Stveptoroccus prieunzorzine and 
H .  inPuerzzm, in the levofloxacin treatment group 
compared with 94% and 79'%,, respectively, in the 
ceftriaxone/cefuroxime group. Levofloxacin was well 
tolerated, with nausea (2%) and diarrhea (1%) being the 
most common adverse events. 
Trovafloxacin has comparable activity to cipro- 
floxacin against H .  ir!flirr.nznc and :\foomxc//n ratnrrlinlis, 
and improved xt ivi ty  ap ins t  Streptocorrrrr pncririiorriac 
and group A streptococci 1401. In addition, it is highly 
active against L;yiofre/ /n  spp. m d  CIiImnjdin pnPrrrnorrine 
and equally effective agaiiist both penicilliii-susceptible 
and -resistant pneumococci. T h e  potent in vitro 
activity of trovafloxacin against pneuniococci and other 
respiratory tract pathogens is currently being assessed in 
clinical trials. 
CONCLUSIONS 
The diverse nature of  LKTI pathogens and the need 
for empirical treatnient, especially in  CAP, necessitates 
the use of  an antibiotic with a spectrum adapted to 
the range of pulmonary pathogens, T h e  increasing 
probleni of  resistance to currently used antibiotics 
necessitates the use of alternative agents. T h e  new 
fluoroquinolones, in contrast to ciprofloxacin, xvhich 
does not have reliable antipneumococcal activity? have 
a broad antibacterial spectrum, enhanced activity aaainst 
Stveptncoccur pririr~mniar, and rapid bactericidal activity. 
Spafloxacin was the first of these new agents to be 
introduced and there are niaiiy compounds currently 
in development. Levofloxacin, which has recently 
become available in the USA, has a similar safety profile 
to ofloxacin, appears to be well tolerated and is not 
associated with the phototoxicity problenis reported 
with spaifloxacin. 
T h e  newer fluoroquinolones could be considered 
for first-line monotherapy for coinniunity-acquired 
LRTI because o f  their wide spectrum of activity, 
clinical efficacy and good safety profile. In nosocomial 
pneumonia, however, because of the prevalence of  
P neviigirrora or Srnph y/orocurs iiiireiis as causative 
pathogens, the results of susceptibility tests and of  
clinical studies should determine the therapy to be 
srlccted. Confirmation of  their cost-etkctiveiiess is 
required in  CAP but, :it present. the results of the 
necessary pharmacoecono~nic studies are not available. 
They could also be used ;IS second-line therapy, in cases 
of failure with other antibiotics, cuch as niacrolidey or  
B-lactanis. Currently thwe is insufiicient in forn~t ior i  
to support their use in combination therapy. Hoxvevcr, 
in the case of levofloxacin, there are considerable 
supporting data on the u!;e of ofloxacin in combination 
therapy. T h e  option of step-dwvn or  switch therapy 
(from oral to intravenous administration or  vice versa) 
is an iniportanr advantage of the new fluoroquinolones. 
In order to deterniinc fully the place ofthese agents 
i n  the treatment of  lower respiratory tract infections, 
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more studies are needed. These include studies to 
determine: the cost-effectiveness of fluoroquinolones 
compared with other agents; the optimal duration of 
treatment based on clinical endpoints rather than on 
fixed duration of treatment; the impact of the use of 
fluoroquinolones on the microbial ecology of the 
patient and people in close contact with the patient; 
and the pediatric use of fluoroquinolones, other than 
in cystic fibrosis. O n  the basis of the information avail- 
able to date, however, the new fluoroquinolones should 
prove to be useful agents for the treatment of lower 
respiratory tract infections. 
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